

Accepted refereed manuscript of:

Bourke L, Bauld L, Bullen C, Cumberbatch M, Giovannucci E, Islami F, McRobbie H, Silverman DT & Catto JWF (2017) E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks, *European Urology*, 71 (6), pp. 915-923.

DOI: [10.1016/j.eururo.2016.12.022](https://doi.org/10.1016/j.eururo.2016.12.022)

© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

Manuscript type: Invited collaborative review

Title: E-cigarettes and Urological Health: Toxicology, Epidemiology and Potential Risks: a collaborative review

Authors: Bourke L¹, Bauld L², Bullen C³, Cumberbatch M⁴, Giovannucci E⁵, Islami F⁶, McRobbie H⁷, Silverman DT⁸ and Catto J.W.F.⁴

Accepted for publication in *European Urology* published by Elsevier.

Affiliations:

1. Faculty of Health and Wellbeing, Sheffield Hallam University, UK.

2. Institute for Social Marketing and UK Centre for Tobacco and Alcohol Studies, University of Stirling, UK.

3. National Institute for Health Innovation, University of Auckland, New Zealand

4. Academic Urology Unit, Department of Oncology and Metabolism, University of Sheffield, UK.

5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, USA.

6. Surveillance and Health Services Research, American Cancer Society, Atlanta.

7. Wolfson Institute of Preventative Medicine and UK Centre for Tobacco and Alcohol Studies, Queen Mary University of London.

8. Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA.

25 **Corresponding author:** Dr Liam Bourke, l.bourke@shu.ac.uk

26

27 **Manuscript Word Count:** 4441

28 **Abstract Word Count:** 287

29

30 **Keywords:** electronic cigarettes, smoking cessation, toxicology, urological health

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Abstract**

52 **Context:** Use of electronic cigarettes (ECs) is on the rise in most high income countries.

53 Smoking conventional cigarettes is a known risk factor for urological malignancy incidence,
54 progression and mortality as well as for other urological health indicators. The potential
55 impact of EC use on urological health is therefore of clinical interest to the urology
56 community.

57 **Objective:** To review the available data on current EC use including potential benefits in
58 urological patients, potential issues linked to toxicology of EC constituents and how this
59 might translate into urological health risks.

60 **Evidence Acquisition:** A Medline search was carried out in August 2016 for studies reporting
61 urological health outcomes and EC use. Snowballing techniques were also used to identify
62 relevant studies from recent systematic reviews. A narrative synthesis of data around EC
63 health outcomes, toxicology, potential use in smoking cessation and health policy was
64 carried out.

65 **Evidence synthesis:** We found no studies to date that have been specifically designed to
66 assess prospectively urological health risks, even in an observational setting. Generating
67 such data would be an important contribution to the debate on the role of ECs in public
68 health and clinical practice. There is evidence from a recent Cochrane review of RCTs that
69 ECs can support smoking cessation. There are emerging data around potentially harmful
70 components of ECs such as tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons and
71 heavy metals could be linked to possible urological health risks.

Conclusions: ECs might be a useful tool to encourage conventional cigarette smoking

cessation. However, data collection around EC specific impact on urological health is needed

to clarify the possible patient benefit, outcomes and adverse events.

Patient summary: Whilst ECs might help some people to stop smoking, their overall impact

on urological health is not clear.

96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119

1. Introduction

Tobacco smoking is an established cause of bladder and kidney cancer (50% and 20% of incident cases, respectively [1]). For people who smoke, there are clear benefits of quitting. For people who don't smoke, or would never have started smoking in the absence of EC, there are potential risks. As such, it is important for urologists and urological health researchers to understand the possible implications of EC use in urology patients.[2]

1.1 What are e-cigarettes?

Electronic cigarettes (ECs) are battery-powered devices that all work by heating a liquid ('e-liquid') to create an aerosol that is then inhaled. The aerosol produced is more commonly referred to as vapour, and the use of the device as 'vaping'. Some are designed to resemble traditional cigarettes ('cigalikes' or first generation products), whereas newer generation (tank systems) are modular and can be personalised. The cigalike devices are closed systems and are, generally, not refillable. They may be made for single use (i.e. disposable) or they can have a rechargeable battery and replaceable cartridges that contain the heating coil (or atomizer) and liquid. The newer generation products are generally greater in size and consist of a high capacity lithium battery, sometimes with variable power, an atomizer, and a tank that the user fills with liquid. The atomizer is usually manually activated, which gives greater control over vapour production than the automated systems. Most people start out using a cigalike device, but regular vapers generally use tank system ECs [3].

There are three main components of the e-liquid; propylene glycol or glycerol or a mix of these, nicotine, and flavouring. The propylene glycol/glycerol mix is important for user satisfaction (e.g. a high propylene glycol content gives a greater 'throat hit'), but may also be important for nicotine delivery.[4] Nicotine concentrations vary from 0 to 36mg/ml, with 18mg/ml being the most commonly used.[5, 6] However the European Tobacco Products Directive, which came into effect on 20 May 2016, now limits the concentration to a maximum of 20mg/ml. The directive also restricts the volume of bottles of e-liquid to 10ml and volume of EC tanks to 2ml, as well as a number of other measures including restrictions on advertising and promotions and packaging and labelling requirements. EC liquid (e-liquid) is available in numerous flavours, which are important for user satisfaction. In Great Britain, the most commonly used flavour by current vapers is tobacco, followed by fruit and mint/menthol flavours.[3] The flavours used are considered safe for oral ingestion, but the effects of heating these and then inhaling them are unknown. Some flavours appear to be more cytotoxic than others (e.g. strawberry [7] and cinnamon [8]) and associated with increased risk of respiratory disease (e.g. diacetyl, [9] which gives a buttery flavour).

Heating nicotine-containing e-liquid produces nicotine-containing vapour; however, the association between the concentration of nicotine in the e-liquid and in vapour is inconsistent. Other factors such as heating of the liquid, voltage and amperage resistance, and how the user inhales on the EC also have a role to play. ECs also do not deliver as much nicotine on a puff by puff basis as standard cigarettes.[10] Therefore, vapers typically take longer puffs than with standard cigarettes (e.g. a mean of 2.4 seconds for conventional cigarettes versus 4.3 seconds for ECs).[11]

1.2. Epidemiology/demographics around EC use

Since being introduced, the prevalence of EC use has seen a relatively rapid increase in many high-income countries from which national longitudinal data are available, notably North American and European countries. For example, the prevalence of ever-use among individuals aged ≥ 15 years in 27 states of the European Union increased from 7.2% in 2012 to 11.9% in 2014 (Table 1).[12] On average, 15.3% of ever e-cigarette users became current users in 2014. The greatest increases in the European Union occurred in Malta (5.5% increase), Ireland (5.1%), Sweden (4.5%), and France (4.3%). In that survey, the lowest prevalence in 2014 was reported from Portugal (5.7%), whereas the prevalence was 10% or more in 15 countries, with the highest prevalence in France (21.3%).[12] Experimenting and ever use of ECs is generally common among youth,[13] but in Europe, prevalence of regular EC use is much higher in older adults who smoke. In 2014, prevalence of ever EC use in individuals aged ≥ 15 years in the United Kingdom was 15.5%, and approximately one quarter of them transitioned to current users.[12] Among adolescents aged 11–18 years in Great Britain, prevalence of ever use of ECs in 2014 was 8.2%, while it was 1.7% for monthly or more use.[14]

On the other hand, prevalence of more regular use is higher in youth than older adults in North America. In 2013, 8.5% and 1.8% of Canadians reported ever and current (past 30-day) use of ECs, respectively.[15] The highest prevalence of current use was in age 20–24 (3.9%), followed by age 15–19 (2.6%).[15] In the United States, the prevalence of current use among individuals aged ≥ 18 years in 2013–2014 was 3.3%.[16] However, there has been a substantial increase in ECs use among high-school students in the United States, with current use prevalence increasing from 1.5% in 2011 to 16.0% in 2015.[17] The recent US

Surgeon General's report warned that in 2014, current use of ECs by young adults 18–24 years of age surpassed that of adults 25 years of age and older. The report points to potentially harmful constituents of ECs: particularly nicotine which can lead to addiction and can harm the developing adolescent brain.[18]

Information on EC use at the national level from countries in other regions is limited. In a survey of Chinese adults (age 15–65 years) in Hong Kong in 2014, the prevalence of ever EC use was 2.3%.[19] Among individuals aged ≥ 15 years in New Zealand in 2014, 13.1% had ever used ECs and only 0.8% were current users. The highest prevalence of current use was in age 22–44 years (1.2%), followed by age ≥ 45 (0.7%).[20] Prevalence of ever and current use of ECs among students aged 13–18 years in South Korea in 2011 was 9.4% and 1.4%, respectively.[21] Since 2011, questions on ECs use have been added to the Global Adult Tobacco Survey (GATS), which is a nationally representative household survey of individuals aged ≥ 15 years in a number of countries.[22] The prevalence of current EC use in four countries with available data was 0.3% in Indonesia and 0.8% in Malaysia in 2011 and 0.9% in Qatar and 1.9% in Greece in 2013.[22] It should be noted that due to rapid changes in prevalence of EC use in some countries, prevalence of use across countries, especially among youth, may not be comparable using results of surveys conducted in different years.

EC use has the potential to help smokers to quit cigarette smoking or reduce smoking intensity.[23] However, one of the primary concerns of EC use is the maintenance of tobacco use in current smokers (without any substantial decrease in smoking intensity), re-initiation in former smokers, and in particular, nicotine dependence in adolescents,[24–28] as EC user adolescents may show a higher intention to smoke traditional cigarettes.[25, 27]

However, in many countries, the rate of EC use by never-smokers or smoking initiation following EC use has been relatively low, although there might be some variations across countries. In a survey conducted in 2014 in the European Union, initiation of tobacco use by using ECs was reported by 0.8% of participants who had used any tobacco product. Use of nicotine-containing EC among never smokers was low (1.3%), with 0.09% reporting daily use.[29] The prevalence of current EC use among never-smokers in 2013 was 0.3% in Canada [15] and 1.4% in the United States.[26] Among adolescents, EC use at least monthly was reported by only 0.2% of adolescents aged 11–18 years in Great Britain in 2014.[14] Among middle and high school students in the United States in 2011–2013, prevalence of current EC use was 0.3% among never smokers.[24] Prevalence of ever and current use of ECs only (no other tobacco products) in age 13–18 years in South Korea in 2011 was 1.4% and 1.1%, respectively.[21] Despite low rates of ECs use among never smoker adolescents, this group could include a substantial number of children, as generally prevalence of tobacco smoking in this age group is low. For example, the group of never smoker students that were current ECs users (0.3% of never smokers) in the United States in 2013 included 263,000 children.[24]

2. Evidence acquisition

In order to identify any eligible trials addressing EC use and urological health outcomes, a search of the electronic databases MEDLINE was carried out from inception to August 2016. MEDLINE search terms were (e-cigarette or electronic-cigarette) AND (bladder or prostate or kidney or urol*). In addition to database searches, recent systematic reviews of EC use were hand searched for any potentially eligible trials. To add context to the any available trials data, evidence around smoking

cessation, available toxicology data and health policy around EC regulations are presented in this review. Quality appraisal was done subjectively according to expertise and clinical judgement of the authors. Given that EC use and urological outcomes is an emerging clinical issue with a fragmentary evidence base and involves rapidly evolving technologies, a narrative synthesis of these data was undertaken.[30]

3. Evidence synthesis

3.1 Current urological health outcomes and trials of EC use

We found no published clinical studies, which are *a priori* designed to evaluate the impact of ECs on urological health outcomes. We were able to find only one published protocol for a prospective observational study that will document hospitalizations and adverse events that could report urological health outcomes (although not specifically designed to do this).[31]

3.2 Toxicity data and potential urological health impacts from ECs

ECs were introduced into the US and UK markets in 2007 [32] and so their long-term health risks are not yet clear. Reducing the use of conventional cigarettes has numerous obvious health benefits including links to incidence and progression of urological malignancies [33] and complications after primary treatment for urological cancer.[34] EC operation does not involve combustion and so no smoke or other harmful combustion products, such as tar and carbon monoxide, are formed. Reduced excretion of tobacco-specific nitrosamines and other carcinogens has been found in the urine of vapers compared with smokers. [35, 36] ECs are thought to be much safer for long-term health by the public than traditional tobacco cigarettes.[37] It is however, important to recognise that these devices are not entirely benign. Due to the nature and components of these devices, ECs have a diverse hazard

profile. Operation of EC at high temperatures can generate relatively high levels of aldehydes [38, 39], which have carcinogenic potential. However vapers naturally avoid this, as it creates an unpleasant taste (commonly known as a 'dry puff')[39, 40]. A recent systematic review highlighted adverse events linked between EC use and the respiratory, gastrointestinal, cardiovascular, neurological and immune system; serious leg burns due to exposure of the battery; serious oral burns, lacerations and fractures from an account of an EC 'explosion'; both accidental and intentional nicotine overdoses (suicide attempts).[41]

Data regarding the constituents of ECs is evolving in the literature. Levels of each component can be varied (e.g. Allen et al (2016) describe over 7000 flavours[42]) and there is heterogeneity amongst manufacturers.[43] For example, nicotine levels were seen to vary from 0 mg/ml to 87 mg/ml across studies, and there were reported deviations from the device label of ingredients of up to 100%.[43] Furthermore, there is inconsistency in the delivery of chemicals within each puff from the same device or brand. This may be due to subtle differences in the size of particulate matter within each refill solution and the delivery system that is used.

A recent review describes chemical profiles of EC solutions, cartridges, aerosols and environmental emissions.[43] Whilst ECs are designed to be devoid of tar, some ECs have been found to contain carcinogens such as tobacco-specific nitrosamines and formaldehyde. Other constituents such as polyaromatic hydrocarbons and heavy metals are known to cause cancer, and nicotine itself is thought by some to pose a urological cancer risk. [44, 45] For instance, polycyclic aromatic hydrocarbons (International Agency for Research on Cancer (IARC), Group 1 (human carcinogen)[46]), which has been associated with bladder

cancer.[47] EC have also been found to contain certain heavy metals, such as lead.[48] Lead exposure has been linked to increased kidney cancer risk. [49, 50] The concentration of lead in EC aerosol is variable but has been suggested in at least one analysis to be comparable to that found in conventional cigarettes.[51] Other heavy metals in EC such as cadmium, nickel and chromium are possible carcinogens (IARC 2b). Nickel, in particular, has been recorded at levels present in ECs that are much higher than conventional cigarettes. [51] Although these heavy metals are linked to an increase cancer risk, they have not yet been linked to urological malignancies.[49] Cresol, which has been found in aerosols from EC cartridges is also found in creosote, a suspect bladder carcinogen.[47]

In addition, in vitro data has demonstrated that EC vapour exposure, independent of nicotine content induces increased cell death. In both normal epithelial cells and cancer cell lines (head and neck squamous cell carcinoma) treated with nicotine free and nicotine-containing vapour, up to a threefold increase in DNA double strand breaks has been reported.[52] Nicotine is also negatively correlated with total sperm motility due to metabolic breakdown products cotinine and trans-3'-hydroxycotinine levels in seminal fluid.[53] Furthermore, cadmium (found in ECs) is associated with low sperm density.[54] Preliminary evidence from a murine model has reported exposure to EC refill liquid can alter anti-oxidant defence and induce histopathological changes reflecting renal collecting duct cell apoptosis.[55]

Whilst there is a theoretic potential for adverse urological health outcomes from the use of ECs it should be stressed that robust data are currently absent to offer a convincing argument for either side of the debate. A recent systematic review of the health

consequences of vaping/ECs highlighted frequent methodological problems with available studies, problematic authorship conflicts of interest, small cohort size, selection bias, conflicting results and a paucity of long-term follow-up data.[48]

3.3 Can ECs help stop tobacco smoking?

The literature on the role ECs play in smoking cessation is growing very slowly, and the messages are somewhat mixed. This section summarizes the current evidence from a range of different study designs and levels of evidence.

3.3.1 Prospective cohort studies

Five studies, with long-term outcomes, have looked at the use of ECs in people who were not ready to quit smoking. One followed 40 smokers over two years and reported that 13% achieved at least six months of CO validated abstinence from conventional cigarettes and 28% had achieved a sustained $\geq 50\%$ reduction from baseline cigarette consumption.[56, 57] The second tested the same approach with 14 smokers with schizophrenia and reported 14% 30-day CO validated abstinence rates at one-year.[58] The third followed a group of 34 smokers for 8 months after discharge from hospital.[59] Over half (53%) reported no longer smoking. In the fourth, 50 smokers were provided with a second-generation device with 9mg/ml concentration of e-liquid. At 6 month follow-up 36% were biochemically validated 7-day point prevalence abstainers.[60] The fifth cohort study followed 71 smokers who purchased an EC from a vape shop. One year after their purchase 41% reported that they had not smoked at all for at least the last 30 days.[61]

311

312 Data are now being reported by the UK stop smoking services. A London-based stop
313 smoking service offered 100 clients, all of whom wanted to quit smoking, a choice of a first
314 or second generation EC.[62] In total, 67 accepted the offer and of these 45 (65%) were
315 recorded as biochemically validated abstainers at the end of treatment (4-weeks post-quit
316 date). The results from this study closely reflect the UK Stop Smoking Service monitoring
317 data from over 450,000 people that made a quit attempt, where 4-week self-reported quit
318 rates were 66% among people who used ECs (n=2221), compared to 48% among people
319 who used combination NRT (n=135,719).

320

321 Although there are data to support ECs as a potential aid to smoking cessation in the
322 general population, it is important to note that in those already diagnosed with cancer,
323 there is less certainty. Prospective cohort data from a major US cancer treatment centre
324 reported that significantly higher percentage of EC users were highly nicotine dependent
325 when compared with nonusers and were twice as likely to be smoking at the time of follow-
326 up as nonusers.[63]

327

328 **3.3.2 Randomised controlled trials**

329 To date only three randomised controlled trials that have examined the effects of EC in
330 helping people stop smoking have been published. One examined their use in people who
331 wanted to quit,[64] and two in those who did not.[65, 66] In a study of people who wanted
332 to quit from New Zealand [64], the investigators compared nicotine-containing ECs (n=289),
333 with 21mg nicotine patches (n=295), and with non-nicotine ECs (placebo ECs, n=73).

Participants were provided with a referral to telephone quitline but with no face-to-face contact. In this minimal support context, there were no significant differences in validated continuous abstinence at six months (7.3% nicotine EC, 5.8% nicotine patch, and 4.1% non-nicotine EC). These findings were similar to an Italian study comparing EC use (two different doses for 12 weeks) to non-nicotine ECs in 300 smokers who were not intending to quit. [65] Biochemically validated six-month abstinence rates (at one-year follow-up) were not significantly different; 13%, 9% and 4% in the three groups, respectively. Both of these pioneering trials were underpowered and used first generation EC products with poor nicotine delivery. These ECs often malfunctioned and neither is now available on the market.

The third trial [66], from Belgium, randomised 48 smokers who did not want to quit to use an EC (a tank system) or no intervention. At 8-week follow-up, 34% of those given an EC to use had quit smoking compared to none in control group. From week 8, all participants were provided with an EC and followed up at 8 months. Among this cohort 19% of early EC users and 25% of the late starters (the control group) had stopped smoking. The results from this study are difficult to interpret because of the small sample size and design.

3.3.3 Systematic reviews

There are now 16 published systematic reviews on ECs for smoking cessation. A recently updated Cochrane review found that ECs with nicotine helped smokers quit for at least 6 months compared with no nicotine ECs (RR= 2.29, 95% CI: 1.05-4.96; 9% vs. 4%). [67] The authors of the review gave these findings a 'low' confidence rating using GRADE standards, not because of poor quality studies, but because there are only two studies. Crucially, the

'low' judgement also means that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. The addition of more trials to this review will further strengthen the conclusions made. Other systematic reviews draw similar conclusions to the Cochrane review (e.g.[68, 69]), unsurprisingly because they include the same studies. The review and meta-analysis by Kalkohern and Glantz [70] came to the opposite conclusion (that EC use is associated with significantly lower odds of achieving abstinence; OR 0.72; 95% CI: 0.57-0.91). The data in this review included reports of many small surveys and cohort studies (all with serious limitations) rendering the findings of this meta-analysis difficult to interpret.

Given that ECs now deliver nicotine to the user in similar quantities as NRT and even cigarettes, there is little reason to doubt they could help people stop smoking. Some estimates of the numbers who have stopped using ECs have been made. For example, Farsalinos estimated 6.1 million European ever EC users have stopped smoking.[71] In England this figure is thought to be around 0.56 million. Further research and monitoring will strengthen confidence in these findings.[72]

3.4 European health policy and ECs

The use of ECs for smoking reduction or cessation is influenced by a range of factors that extend beyond the safety and efficacy of these devices. Regulation also affects their use, in particular policies that may result in changes to the price, availability or promotion of the products.[73] The global context for EC regulation is highly variable.[74] In many countries such as Argentina, Brazil, Indonesia, and Singapore, the import, distribution and sale of ECs

is banned. Other countries such as New Zealand, South Africa and Switzerland have implemented a two tier system where ECs themselves and nicotine-free cartridges or e-liquid can be sold but nicotine-containing refills or e-liquid are prohibited. Other countries permit their import and sale but certain restrictions on age of sale or marketing are in place. Policies have evolved as use has become more prevalent and governments have responded to a range of concerns often about youth uptake, addictiveness or safety. Ironically, many jurisdictions now have more restrictive regulation on ECs than tobacco products.

In the European Union (EU), EC use is prevalent and countries have taken a range of approaches to regulation.[29] From May 2016 the revised EU Tobacco Products Directive (TPD) was implemented and article 20 of the Directive applies to ECs and refill containers that do not have a medicinal license.[75] Only one device, E-Voke (manufactured by British American Tobacco) has been granted a medicinal license but is not yet available on prescription or as an over the counter medication.[76] The EU TPD requires manufacturers and importers of ECs to comply with a notification process that involves providing data on: ingredients and emissions; nicotine delivery and uptake; health and addictive effects; the product components and production process; and a declaration on safety and quality when used as intended. It is anticipated that this process will remove some products from the market that can't meet these requirements.

The TPD also places a limit on nicotine concentration with devices that do not have a medicinal license limited to 20mg/ml and refill containers up to a maximum volume of 10ml. The basis for this requirement is contested and some concerns have been expressed about this limit in terms of delivering nicotine to smokers who are highly dependent.[77] ECs must

also be secure in terms of leakage and breakage, be child and tamper proof and contain a leaflet with warnings, instructions and further information. Packaging must contain a warning label about nicotine being a highly addictive substance and promotional elements on packaging are also subject to regulation. Some forms of marketing are also restricted under the TPD including the prohibition of all cross border advertising and sponsorship although other forms of marketing such as billboards and point of sale are at the discretion of member states. Finally, annual submissions on products are required to be submitted to governments and a system for collecting information on adverse effects on health must be in place. Other policy issues such as age of sale, use in public places and the regulation of flavours are the responsibility of national governments.

4. Discussion

We were not able to find any clinical studies with prospective outcomes assessing EC use and urological outcomes. We have presented data around toxicology of compounds found in EC constituents and how this might impact urological health, but these must be viewed as hypothesis generating and treated with caution. As such the use and potential outcomes associated with EC use in urological patient populations is still to be determined. Some international studies, such as the International Tobacco Control Survey,[78] are already providing useful data allowing comparisons of the prevalence of EC use in adults and young people, impact on smoking cessation, and harm perceptions to be examined across countries. In the UK, Cancer Research UK and Public Health England have established the UK Electronic Cigarette Research forum (UKECRF) which brings together researchers from a range of disciplines three times a year to build new collaborations and pursue studies that aim to address research gaps. The forum also produces a monthly evidence bulletin

summarising new studies. Networks of this type are needed in other countries to develop high quality proposals for EC research and generate evidence to inform policy and practice in this rapidly developing field. More research on patterns of tobacco use after e-cigarettes use, in particular among youth, is needed.[79] Also, little information is available on prevalence of use of nicotine-containing and non-nicotine e-cigarettes. Appropriate regulations are needed to protect non-smokers especially adolescents, whilst granting access to smokers to support cessation. In terms of urological health outcomes specifically, data around vapour emission quantities and compositions would be helpful and to work towards validated and standardised contents of ECs. This is an important public health question because EC have been popularised as an aid to smoking cessation, particularly among teenagers. Given the long latency of most cancers, it may take at least 15 years of follow up to identify urological cancer risk among EC users. Analysis of the urine of EC users for compounds such as nitrosamines, aldehydes, lead, arsenic, nickel, chromium and how these are associated with the development of urological malignancies over time would also be a valuable addition to the knowledge base. There is also the challenge of differentiating between conventional cigarette and EC induced health problems, given that most EC users also smoke conventional cigarettes. In this regard, methodologically robust prospective studies looking at urological malignancies in EC users would be valuable data to add to this debate.

Figure Legends:

Table 1: Selected representative prevalences of e-cigarette use

453 **Funding:** This review received no funding.

454

455 **Author contributions:** The views expressed here may not represent those of the authors’

456 organizations.

457 Liam Bourke had full access to all the data in the study and takes responsibility for the

458 integrity of the data and the accuracy of the analysis.

459 **Study concept and design:** Bourke, Catto

460 **Acquisition of data:** Bourke, Bauld, Bullen, Cumberbatch, Giovannucci, Islami, McRobbie,

461 Silverman and Catto.

462 **Analysis and interpretation of data:** Bourke, Bauld, Bullen, Cumberbatch, Giovannucci,

463 Islami, McRobbie, Silverman and Catto.

464 **Drafting of the manuscript:** Bourke, Bauld, Bullen, Cumberbatch, Giovannucci, Islami,

465 McRobbie, Silverman and Catto.

466 **Critical revision of the manuscript for important intellectual content:**

467 Bourke, Bauld, Bullen, Cumberbatch, Giovannucci, Islami, McRobbie, Silverman and Catto.

468 **Statistical analysis:** None.

469 **Obtaining funding:** None.

470 **Administrative, technical, or material support:** None.

471 **Supervision:** Catto.

472 **Other (specify):** None.

473

474

475

476

478 **Table 1.**

Reference; country, year	Age, no. of participants	Prevalence		
		E-cigarette use	Overall, %	Never tobacco smokers, %
Filippidis et al. [12];* European Union (27 countries), 2012–2014	≥15 years 2012: 26,751 2014: 26,792	Ever use, 2012 Ever use, 2014 Transition of ever to current users	7.2 11.9 15.3 (F 14.2; M 17.7)	
Eastwood et al. [14]; Great Britain, 2013–2014	11–18 years 2013: 2,062 2014: 1,952	< monthly, 2013 Monthly or more, 2013 < monthly, 2014 Monthly or more, 2014	3.7 0.9 ‡ 6.5 1.7 ‡	0.6 0.1 1.5 0.2
Hu et al. [16]; USA, 2013–2014	≥18 years 75,233	Every or some days All 18–24 years 25–44 45–64 ≥ 65 Every/some days or rarely	3.3 (F 2.8, M 4.0) 5.5 4.4 2.8 0.9 6.6 (F 7.9, M 5.5)	
Czoli et al. [15]; Canada, 2013	≥15 years ~2.5 million	Use in the past 30 days All 15–19 years 25–44 45–64 ≥ 45 Ever use	1.8 (F 1.8, M 1.8) 2.6 (F 2.1, M 3.0) 3.9 (F 3.5, M 4.3) 2.4 (F NR, M 3.0) 1.0 (F 1.2, M 0.8) 8.5 (F 8.1, M 8.9)	0.5 (F 0.5, M 0.5) 3.6 (F 3.4, M 3.9)
Singh et al. [17]; USA, 2011–2015	Middle or high school students 2011: 18,866 2015: 17,711	Use in the past 30 days High school, 2015 Middle school, 2015 High school, 2011 Middle school, 2011	16.0 (F 12.8, M 19.0) 5.3 (F 4.8, M 5.9) 1.5 0.6	
Jiang et al. [19]; Hong Kong, 2014	15–65 years 809	Ever use All 15–29 years 30–49 50–65	2.3 (F 1.3, M 3.6) 5.2 1.8 1.0	1.0
Li et al. [20]; New Zealand, 2014	≥15 years 2,594	Monthly or more All 15–17 years 18–24 25–44 ≥ 45 Ever use	0.8 (F 1.0, M 0.5) 0.0 0.2 1.2 0.7 13.1 (F 12.8, M 13.7)	0.1
Lee et al. [21]; South Korea, 2011	13–18 years (students) 75,643	Use in the past 30 days All students Grade 7 8 9 10 11 12 Ever use	4.7 (F 1.8, M 7.8) 2.0 3.3 4.7 7.1 6.0 6.2 9.4	0.6
Palipudi et al. [22]; Greece, Indonesia,	≥15 years Greece (9,357),	Current use ** Greece		

Reference; country, year	Age, no. of participants	Prevalence		
		E-cigarette use	Overall, %	Never tobacco smokers, %
Malaysia, and Qatar, 2011–2013	Indonesia (8,303)	All	1.9 (F 1.8, M 7.8)	1.1 ¶
		15–24 years	0.0	
		25–44	2.8	
		45–64	2.7	
		≥ 65	0.8	
	Malaysia (4,244)	Indonesia		
		All	0.3 (F 1.8, M 7.8)	0.0 ¶
		15–24 years	0.2	
		25–44	0.3	
		45–64	0.3	
		≥ 65	0.0	
	Qatar (8,389)	Malaysia		
		All	0.8 (F 1.8, M 7.8)	0.1 ¶
		15–24 years	4.4	
		25–44	5.0	
		45–64	0.0	
		≥ 65	0.0	
		Qatar		
		All	0.9 (F 1.8, M 7.8)	0.2 ¶
		15–24 years	0.5	
		25–44	1.0	
		45–64	1.3	
		≥ 65	0.0	
Bunnell et al. [24]; USA, 2011–2013	Middle or high school students 61,932	Use in the past 30 days		0.3
		Ever use	6.1	0.9

F, female; M, male; NR, not-reported.

* Prevalences for individual countries are also presented in the article.

** Those who responded “daily or less than daily” to the question “Do you currently use e-cigarettes on a daily basis, less than daily, or not at all?”

‡ Males were 2.5-times more likely to be monthly or more users than females.

¶ Among those with no current tobacco smoking.

References

- [1] Purdue MP, Silverman DT. Clearing the Air: Summarizing the Smoking-related Relative Risks of Bladder and Kidney Cancer. *Eur Urol.* 2016;70:467-8.
- [2] Yeh JS, Bullen C, Glantz SA. CLINICAL DECISIONS. E-Cigarettes and Smoking Cessation. *N Engl J Med.* 2016;374:2172-4.
- [3] Health AoSa. ASH Fact Sheet on the use of electronic cigarettes among adults in Great Britain. London, UK: ASH UK; 2015.
- [4] Yan XS, D'Ruiz C. Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. *Regulatory toxicology and pharmacology: RTP.* 2014.
- [5] Etter J-F, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. *Addiction.* 2011;106:2017-28.
- [6] Dawkins L, Turner J, Roberts A, Soar K. 'Vaping' profiles and preferences: an online survey of electronic cigarette users. *Addiction.* 2013;108:1115-25.
- [7] Leigh NJ, Lawton RI, Hershberger PA, Goniewicz ML. Flavourings significantly affect inhalation toxicity of aerosol generated from electronic nicotine delivery systems (ENDS). *Tob Control.* 2016.
- [8] Behar RZ, Luo W, Lin SC, Wang Y, Valle J, Pankow JF, et al. Distribution, quantification and toxicity of cinnamaldehyde in electronic cigarette refill fluids and aerosols. *Tob Control.* 2016.
- [9] Kreiss K, Gomaa A, Kullman G, Fedan K, Simoes EJ, Enright PL. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. *N Engl J Med.* 2002;347:330-8.
- [10] Goniewicz ML, Hajek P, McRobbie H. Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications. *Addiction.* 2014;109:500-7.
- [11] Hua M, Yip H, Talbot P. Mining data on usage of electronic nicotine delivery systems (ENDS) from YouTube videos. *Tobacco Control.* 2013;22:103-6.
- [12] Filippidis FT, Lavery AA, Gerovasili V, Vardavas CI. Two-year trends and predictors of e-cigarette use in 27 European Union member states. *Tobacco control.* 2016.
- [13] Vardavas CI, Filippidis FT, Agaku IT. Determinants and prevalence of e-cigarette use throughout the European Union: a secondary analysis of 26 566 youth and adults from 27 Countries. *Tobacco control.* 2015;24:442-8.
- [14] Eastwood B, Dockrell MJ, Arnott D, Britton J, Cheeseman H, Jarvis MJ, et al. Electronic cigarette use in young people in Great Britain 2013-2014. *Public Health.* 2015;129:1150-6.
- [15] Czoli CD, Reid JL, Rynard VL, Hammond D. Tobacco Use in Canada: Patterns and Trends, 2015 Edition. Special Supplement: E-cigarettes in Canada. Waterloo, Canada: Propel Centre for Population Health Impact, University of Waterloo.
- [16] Hu SS, Neff L, Agaku IT, Cox S, Day HR, Holder-Hayes E, et al. Tobacco Product Use Among Adults - United States, 2013-2014. *MMWR Morb Mortal Wkly Rep.* 2016;65:685-91.
- [17] Singh T, Arrazola RA, Corey CG, Husten CG, Neff LJ, Homa DM, et al. Tobacco Use Among Middle and High School Students--United States, 2011-2015. *MMWR Morb Mortal Wkly Rep.* 2016;65:361-7.

552 [18] E-cigarette use among youth and young adults: a report of the Surgeon General.
553 Accessed 09/12/16 at [http://e-](http://e-cigarettes.surgeongeneral.gov/documents/2016_SGR_Full_Report_non-508.pdf)
554 [cigarettes.surgeongeneral.gov/documents/2016_SGR_Full_Report_non-508.pdf](http://e-cigarettes.surgeongeneral.gov/documents/2016_SGR_Full_Report_non-508.pdf).
555 2016.

556 [19] Jiang N, Chen J, Wang MP, McGhee SM, Kwong AC, Lai VW, et al. Electronic
557 cigarette awareness and use among adults in Hong Kong. *Addict Behav.*
558 2016;52:34-8.

559 [20] Li J, Newcombe R, Walton D. The prevalence, correlates and reasons for using
560 electronic cigarettes among New Zealand adults. *Addict Behav.* 2015;45:245-51.

561 [21] Lee S, Grana RA, Glantz SA. Electronic cigarette use among Korean
562 adolescents: a cross-sectional study of market penetration, dual use, and
563 relationship to quit attempts and former smoking. *J Adolesc Health.* 2014;54:684-90.

564 [22] Palipudi KM, Mbulo L, Morton J, Mbulo L, Bunnell R, Blotcher-Nelson G, et al.
565 Awareness and Current Use of Electronic Cigarettes in Indonesia, Malaysia, Qatar,
566 and Greece: Findings From 2011-2013 Global Adult Tobacco Surveys. *Nicotine &*
567 *tobacco research : official journal of the Society for Research on Nicotine and*
568 *Tobacco.* 2016;18:501-7.

569 [23] Beard E, West R, Michie S, Brown J. Association between electronic cigarette
570 use and changes in quit attempts, success of quit attempts, use of smoking
571 cessation pharmacotherapy, and use of stop smoking services in England: time
572 series analysis of population trends. *BMJ.* 2016;354:i4645.

573 [24] Bunnell RE, Agaku IT, Arrazola RA, Apelberg BJ, Caraballo RS, Corey CG, et
574 al. Intentions to smoke cigarettes among never-smoking US middle and high school
575 electronic cigarette users: National Youth Tobacco Survey, 2011-2013. *Nicotine &*
576 *tobacco research : official journal of the Society for Research on Nicotine and*
577 *Tobacco.* 2015;17:228-35.

578 [25] Leventhal AM, Strong DR, Kirkpatrick MG, Unger JB, Sussman S, Riggs NR, et
579 al. Association of Electronic Cigarette Use With Initiation of Combustible Tobacco
580 Product Smoking in Early Adolescence. *JAMA.* 2015;314:700-7.

581 [26] McMillen RC, Gottlieb MA, Shaefer RM, Winickoff JP, Klein JD. Trends in
582 Electronic Cigarette Use Among U.S. Adults: Use is Increasing in Both Smokers and
583 Nonsmokers. *Nicotine & tobacco research : official journal of the Society for*
584 *Research on Nicotine and Tobacco.* 2015;17:1195-202.

585 [27] Wang MP, Ho SY, Leung LT, Lam TH. Electronic cigarette use and its
586 association with smoking in Hong Kong Chinese adolescents. *Addict Behav.*
587 2015;50:124-7.

588 [28] Barrington-Trimis JL, Urman R, Leventhal AM, Gauderman WJ, Cruz TB,
589 Gilreath TD, et al. E-cigarettes, Cigarettes, and the Prevalence of Adolescent
590 Tobacco Use. *Pediatrics.* 2016;138.

591 [29] Farsalinos KE, Poulas K, Voudris V, Le Houezec J. Electronic cigarette use in
592 the European Union: analysis of a representative sample of 27 460 Europeans from
593 28 countries. *Addiction.* 2016.

594 [30] The Editors. Reviews: making sense of an often tangled skein of evidence.
595 *Annals of internal medicine.* 2005;142:1019-20.

596 [31] Manzoli L, La Vecchia C, Flacco ME, Capasso L, Simonetti V, Boccia S, et al.
597 Multicentric cohort study on the long-term efficacy and safety of electronic cigarettes:
598 study design and methodology. *BMC public health.* 2013;13:883.

599 [32] Orellana-Barrios MA, Payne D, Mulkey Z, Nugent K. Electronic Cigarettes-A
600 Narrative Review for Clinicians. *The American journal of medicine.* 2015;128:674-81.

- [33] Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. *Eur Urol*. 2015;70(3):458-66.
- [34] Byun DJ, Cohn MR, Patel SN, Donin NM, Sosnowski R, Bjurlin MA. The Effect of Smoking on 30-Day Complications Following Radical Prostatectomy. *Clin Genitourin Cancer*. 2016.
- [35] Kotandeniya D, Carmella SG, Pillsbury ME, Hecht SS. Combined analysis of N'-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in the urine of cigarette smokers and e-cigarette users. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2015;1007:121-6.
- [36] Hecht SS, Carmella SG, Kotandeniya D, Pillsbury ME, Chen M, Ransom BWS, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. *Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco*. 2015;17:704-9.
- [37] Martinez-Sanchez JM, Fu M, Martin-Sanchez JC, Ballbe M, Salto E, Fernandez E. Perception of electronic cigarettes in the general population: does their usefulness outweigh their risks? *BMJ open*. 2015;5:e009218.
- [38] Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. *The New England Journal of Medicine*. 2015;372:392-4.
- [39] Farsalinos KE, Voudris V, Poulas K. E-cigarettes generate high levels of aldehydes only in 'dry puff' conditions. *Addiction*. 2015;110:1352-6.
- [40] Nitzkin JL, Farsalinos K, Siegel M. More on hidden formaldehyde in e-cigarette aerosols. *The New England Journal of Medicine*. 2015;372:1575.
- [41] Hua M, Talbot P. Potential health effects of electronic cigarettes: A systematic review of case reports. *Prev Med Rep*. 2016;4:169-78.
- [42] Allen JG, Flanigan SS, LeBlanc M, Vallarino J, MacNaughton P, Stewart JH, et al. Flavoring Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 Products, Including Fruit-, Candy-, and Cocktail-Flavored E-Cigarettes. *Environmental health perspectives*. 2016;124:733-9.
- [43] Cheng T. Chemical evaluation of electronic cigarettes. *Tob Control*. 2014;23 Suppl 2:ii11-7.
- [44] Cumberbatch MG, Cox A, Teare D, Catto JW. Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2015;1:1282-90.
- [45] Yuge K, Kikuchi E, Hagiwara M, Yasumizu Y, Tanaka N, Kosaka T, et al. Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer. *Mol Cancer Ther*. 2015;14:2112-20.
- [46] Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, et al. A review of human carcinogens--Part F: chemical agents and related occupations. *Lancet Oncol*. 2009;10:1143-4.
- [47] Silverman DT; Devesa SS; Moore LE; Rothman N. Bladder Cancer. In: Schottenfeld D, Fraumeni JF Jr. eds. *Cancer Epidemiology and Prevention*. 3rd Ed. New York: Oxford University Press.2006.
- [48] Pisinger C, Dossing M. A systematic review of health effects of electronic cigarettes. *Prev Med*. 2014;69:248-60.
- [49] Boffetta P, Fontana L, Stewart P, Zaridze D, Szeszenia-Dabrowska N, Janout V, et al. Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a case-control study from Central and Eastern Europe. *Occupational and environmental medicine*. 2011;68:723-8.

650 [50] Liao LM, Friesen MC, Xiang YB, Cai H, Koh DH, Ji BT, et al. Occupational Lead
651 Exposure and Associations with Selected Cancers: The Shanghai Men's and
652 Women's Health Study Cohorts. *Environmental health perspectives*. 2016;124:97-
653 103.

654 [51] Williams M, Villarreal A, Bozhilov K, Lin S, Talbot P. Metal and silicate particles
655 including nanoparticles are present in electronic cigarette cartomizer fluid and
656 aerosol. *PloS one*. 2013;8:e57987.

657 [52] Yu V, Rahimy M, Korrapati A, Xuan Y, Zou AE, Krishnan AR, et al. Electronic
658 cigarettes induce DNA strand breaks and cell death independently of nicotine in cell
659 lines. *Oral Oncol*. 2016;52:58-65.

660 [53] Pacifici R, Altieri I, Gandini L, Lenzi A, Pichini S, Rosa M, et al. Nicotine,
661 cotinine, and trans-3-hydroxycotinine levels in seminal plasma of smokers: effects on
662 sperm parameters. *Ther Drug Monit*. 1993;15:358-63.

663 [54] Saaranen M, Kantola M, Saarikoski S, Vanha-Perttula T. Human seminal
664 plasma cadmium: comparison with fertility and smoking habits. *Andrologia*.
665 1989;21:140-5.

666 [55] Golli NE, Jrad-Lamine A, Neffati H, Dkhili H, Rahali D, Dallagi Y, et al. Impact of
667 e-cigarette refill liquid exposure on rat kidney. *Regul Toxicol Pharmacol*.
668 2016;77:109-16.

669 [56] Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C. Effect
670 of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and
671 cessation: a prospective 6-month pilot study. *BMC public health*. 2011;11:786.

672 [57] Polosa R, Morjaria JB, Caponnetto P, Campagna D, Russo C, Alamo A, et al.
673 Effectiveness and tolerability of electronic cigarette in real-life: a 24-month
674 prospective observational study. *Internal and emergency medicine*. 2013:[Epub
675 ahead of print].

676 [58] Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R. Impact of an
677 electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a
678 prospective 12-month pilot study. *International journal of environmental research and*
679 *public health*. 2013;10:446-61.

680 [59] Pacifici R, Pichini S, Graziano S, Pellegrini M, Massaro G, Beatrice F.
681 Successful Nicotine Intake in Medical Assisted Use of E-Cigarettes: A Pilot Study.
682 *International journal of environmental research and public health*. 2015;12:7638-46.

683 [60] Polosa R, Caponnetto P, Maglia M, Morjaria JB, Russo C. Success rates with
684 nicotine personal vaporizers: a prospective 6-month pilot study of smokers not
685 intending to quit. *BMC public health*. 2014;14:1159.

686 [61] Polosa R, Caponnetto P, Cibella F, Le-Houezec J. Quit and smoking reduction
687 rates in vape shop consumers: a prospective 12-month survey. *International journal*
688 *of environmental research and public health*. 2015;12:3428-38.

689 [62] Hajek P, Corbin L, Ladmore D, Spearing E. Adding E-Cigarettes to Specialist
690 Stop-Smoking Treatment: City of London Pilot Project. *Journal of Addiction*
691 *Research & Therapy*. 2015;6:244.

692 [63] Borderud SP, Li Y, Burkhalter JE, Sheffer CE, Ostroff JS. Electronic cigarette
693 use among patients with cancer: characteristics of electronic cigarette users and
694 their smoking cessation outcomes. *Cancer*. 2014;120:3527-35.

695 [64] Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al.
696 Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet*.
697 2013;382:1629-37.

698 [65] Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al.
699 Efficiency and Safety of an eElectronic cigAreTte (ECLAT) as Tobacco Cigarettes

Substitute: A Prospective 12-Month Randomized Control Design Study. PloS one. 2013;8:e66317.

[66] Adriaens K, Van Gucht D, Declerck P, Baeyens F. Effectiveness of the Electronic Cigarette: An Eight-Week Flemish Study with Six-Month Follow-up on Smoking Reduction, Craving and Experienced Benefits and Complaints. International journal of environmental research and public health. 2014;11:11220-48.

[67] Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P. Electronic cigarettes for smoking cessation. The Cochrane Database of Systematic Reviews. 2016;CD010216.

[68] Rahman MA, Hann N, Wilson A, Mnatzaganian G, Worrall-Carter L. E-cigarettes and smoking cessation: evidence from a systematic review and meta-analysis. PloS one. 2015;10:e0122544.

[69] Khoudigian S, Devji T, Lytvyn L, Campbell K, Hopkins R, O'Reilly D. The efficacy and short-term effects of electronic cigarettes as a method for smoking cessation: a systematic review and a meta-analysis. International Journal of Public Health. 2016;61:257-67.

[70] Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. The Lancet Respiratory Medicine. 2016;4:116-28.

[71] Farsalinos KE, Poulas K, Voudris V, Le Houezec J. Electronic cigarette use in the European Union: analysis of a representative sample of 27 460 Europeans from 28 countries. Addiction (Abingdon, England). 2016.

[72] West R, Shahab L, Brown J. Estimating the population impact of e-cigarettes on smoking cessation in England. Addiction. 2016;111:1118-9.

[73] Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction Accessed 01/09/16 at <https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction-0>.

[74] Rose A, Fillion KB, Eisenberg MJ, Franck C. Electronic cigarettes: A comparison of national regulatory approaches. Can J Public Health. 2015;106:e450-3.

[75] European Commission. European Union (2016) EU Tobacco Directive. Revision of the Tobacco Products Directive. Accessed 01/09/16 at http://ec.europa.eu/health/tobacco/products/revision/index_en.htm

[76] Medicines and Healthcare Products Regulatory Agency. e-Voke 10mg electronic inhaler, PL42601/0003 e-Voke 15mg electronic inhaler PL42601/004. Accessed 01/09/16 at <http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con475307.pdf>.

[77] Munafo M. What a drag. New Sci. 2016;229:28-9.

[78] Adkison SE, O'Connor RJ, Bansal-Travers M, Hyland A, Borland R, Yong HH, et al. Electronic nicotine delivery systems: international tobacco control four-country survey. American journal of preventive medicine. 2013;44:207-15.

[79] Etter JF, Bullen C, Flouris AD, Laugesen M, Eissenberg T. Electronic nicotine delivery systems: a research agenda. Tob Control. 2011;20:243-8.